CORT (Corcept Therapeutics Corp) Earnings growth in current year
Corcept Therapeutics (CORT) is expanding its presence in the treatment of endocrine pathologies and oncology. The business model relies on the high margins of mass drug production, while operational leverage is based on the outsourcing of mifepristone manufacturing. The current YoY EPS growth rate confirms profit protection, where 175.80 serves as the base parameter value, capturing the earnings per share dynamics relative to the previous year.
Financial and market metric breakdowns for Corcept Therapeutics Inc. (CORT)
- share price and expert price forecast:
- business market valuation indicators:
- book capitalization data:
- debt burden and liquidity indicators:
Debt to Equity Corcept Therapeutics|CORT - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Corcept Therapeutics Inc.|CORT - Company Debts|Debts to Net Assets Corcept Therapeutics Incorporated|CORT - Company Long-Term Debt|Company Current Liabilities Corcept Therapeutics|Quick Liquidity Indicator corcept.com
- earnings and valuation multiples information:
CORT - Company Net Income|Expected Net Profit Corcept Therapeutics|CORT - Price to Earnings Ratio|Future Price to Earnings Multiple Corcept Therapeutics|CORT - PEG Multiple|Enterprise Value to EBITDA Ratio Corcept Therapeutics|CORT - Operating profit EBITDA|Net earnings per one share for the last twelve months Corcept Therapeutics|CORT - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months corcept.com|CORT - Net earnings per share growth this year|Projected earnings per share increase next year Corcept Therapeutics
- revenue and sales proceeds data:
Basic company analysis:CORT - Corcept Therapeutics Corp
This indicator measures the annual growth rate of earnings per share, allowing investors to assess business scaling efficiency and its current lifecycle stage. By analyzing year-over-year EPS dynamics, one can confirm the exceptional macroeconomic resilience of Corcept Therapeutics (CORT), as stable demand for endocrine pathology treatments offsets market cyclicality and seasonal fluctuations.
Main competitors
ASND: Net earnings per one share growth for the current year|MDGL (Madrigal Corp) - Earnings growth in current year|Earnings growth in current year Rhythm Pharmaceuticals|Earnings growth in current year AKRO|Earnings per share growth in current year MTSR (Metsera, Inc.)|Earnings per share growth in current year moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth rate in current year|NAMS - Earnings per share growth in current year|SLNO: Earnings per share growth in current year|FOLD: Earnings growth in current year|ETNB - Expected net earnings per share growth this year|Earnings per share growth in current year Agios Corp|Structure Corp (GPCR) - Expected net earnings per share growth this year|Earnings per share growth in current year mimedx.com (MDXG)|Net earnings per share growth this year rezolutebio.com RZLT|Earnings per share growth in current year Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Earnings per share growth in current year|ALT: Net earnings per share growth this year|AARD - Earnings growth in current year|SGMT: Earnings growth in current year|Earnings per share growth rate in current year BioAge Labs, Inc. (BIOA)|Earnings per share growth in current year Biomea Fusion Inc|Earnings per share growth this year QNCX (Quince Therapeutics)|Net earnings per share growth this year GUTS (Fractyl Health)|Net earnings per one share growth for the current year VTVT|Agape ATP Corporation - Net earnings per share growth this year|Earnings per share increase in current year PLUR|Synlogic Inc. - Earnings growth in current year|LPCN (Lipocine) - Earnings per share growth this year|MTNB (Matinas BioPharma Holdings Inc.) - Net earnings per share growth this year|SPRB (Spruce Biosciences, Inc.) - Earnings per share growth in current year|GLTO (galecto.com) - Earnings growth in current year|Net earnings per share growth this year carmellrx.com (CTCX)|Earnings per share growth in current year Lumos Pharma (LUMO)|ONVO (Organovo Holdings) - Earnings per share increase in current year|radiuspharm.com - Net earnings per share growth this year
